Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis.
Jinqi Liu, Yicong Li, Kai Fu et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the AVERT-2 phase III trial evaluated the predictive value of inflammatory biomarkers in patients with early rheumatoid arthritis (RA) who were naive to disease-modifying antirheumatic drugs. It found that high baseline interleukin-10 (IL-10) levels were associated with a greater probability of achieving clinical response to abatacept and methotrexate (MTX) compared to placebo and MTX, with significant reductions in disease activity (P < 0.03 to P < 0.0007).
Key findings
- High baseline IL-10 levels correlated with better treatment response to abatacept and MTX.
- 47 out of 103 biomarkers showed significant reduction in pharmacodynamic changes with abatacept and MTX.
- 18 biomarkers correlated with baseline disease activity in the study population.
- Higher baseline IL-10 levels were linked to lower bone erosive development with abatacept and MTX.
Why it matters
Identifying predictive biomarkers like IL-10 can help clinicians tailor treatment strategies for patients with early RA, potentially improving outcomes by selecting those more likely to respond to specific therapies.